Podowart is a clinically formulated topical solution designed for the targeted removal of common warts, plantar warts, and other benign epithelial growths caused by the human papillomavirus (HPV). Its active ingredient, podophyllotoxin, acts as a potent cytotoxic agent that precisely destroys wart tissue while minimizing damage to surrounding healthy skin. This prescription-strength treatment offers a reliable, non-invasive alternative to surgical procedures, providing patients and healthcare providers with a controlled, effective option for managing cutaneous warts. With a well-established efficacy profile and clear application protocols, Podowart represents a first-line therapeutic choice in dermatological practice for appropriate patient populations.

Features

• Contains 0.5% podophyllotoxin as the active pharmaceutical ingredient
• Available in solution or cream formulations for precise application
• Ethanol-based vehicle ensuring rapid drying and reduced spread to adjacent skin
• Single-use applicators or brush-tip bottles for hygienic, controlled dosing
• Stable chemical composition with a shelf life of 24 months when stored correctly
• Prescription-only status ensuring professional oversight of treatment

Benefits

• Targeted Destruction: Selectively eradicates wart tissue through inhibition of microtubule assembly, causing necrosis of infected cells.
• Reduced Recurrence: Complete eradication of visible wart tissue and subclinical HPV infection decreases likelihood of reappearance.
• Minimal Scarring: Non-invasive application preserves underlying dermal structure, unlike surgical excision or cryotherapy.
• Patient-Applied Convenience: Allows for home-based treatment under medical guidance, reducing clinic visits.
• Cost-Effective Management: Lower overall treatment cost compared to repeated procedural interventions.
• Rapid Clinical Response: Most patients observe significant reduction in wart size within 1–2 weeks of initiated therapy.

Common use

Podowart is primarily indicated for the treatment of external genital warts (condylomata acuminata), though it is also used off-label for common warts (verruca vulgaris) and plantar warts when clinically appropriate. It is not suitable for mucosal surfaces, intravaginal, intra-anal, or oral warts. Treatment should only commence after confirmed diagnosis by a healthcare professional to exclude malignant or premalignant conditions. Ideal candidates are immunocompetent adults with limited, accessible wart burden who can comply with precise application instructions. Pediatric use is generally contraindicated due to increased systemic absorption risk.

Dosage and direction

Apply twice daily (morning and evening) for 3 consecutive days, followed by a 4-day treatment-free interval. This one-week cycle may be repeated for up to 4 cycles or until complete clearance occurs. Using the supplied applicator or brush, apply solution precisely to cover each wart, avoiding surrounding skin. Allow to dry completely before allowing skin-to-skin contact or clothing coverage. Maximum treated area should not exceed 10 cm², and total volume per application should not exceed 0.5 mL. Wash hands thoroughly immediately after application. Do not apply to bleeding, irritated, or broken skin.

Precautions

• For external use only. Avoid contact with eyes, mucous membranes, and non-affected skin.
• Do not apply to large areas or numerous warts simultaneously due to systemic absorption risk.
• Use with caution in patients with impaired skin barrier function (eczema, psoriasis) or diabetes.
• Pregnancy Category C: Contraindicated during pregnancy and in women attempting conception.
• Breastfeeding individuals should avoid chest application and practice meticulous hand hygiene.
• Sun exposure to treated areas should be minimized due to potential photosensitivity.
• Regular clinical monitoring is recommended to assess response and detect adverse reactions.

Contraindications

• Known hypersensitivity to podophyllotoxin or any formulation components
• Pregnancy, lactation, or women not using effective contraception
• Patients with diabetes or circulatory disorders affecting treatment area
• Application to moles, birthmarks, or unusual lesions not diagnosed as warts
• Use on facial warts or areas with compromised skin integrity
• Children under 12 years of age
• Patients with bleeding disorders or on anticoagulant therapy

Possible side effect

• Local skin reactions: erythema (90%), burning sensation (75%), pain (60%), itching (45%)
• Erosion or ulceration at application site (30%)
• Dryness, scaling, or peeling of skin (25%)
• Hypopigmentation or hyperpigmentation changes (15%)
• Allergic contact dermatitis (5%)
• Rare systemic effects: nausea, vomiting, or peripheral neuropathy with excessive application
• Secondary bacterial infection if proper hygiene not maintained

Drug interaction

No formal drug interaction studies have been conducted. Theoretical interactions include:

• Enhanced systemic absorption when used with occlusive dressings or other topical agents
• Potential increased toxicity when used concomitantly with other cytotoxic medications
• Possible enhanced effect with drugs that inhibit metabolic enzymes CYP2C9 and CYP3A4
• Reduced efficacy with immunosuppressive therapies
• Consult healthcare provider regarding use with other topical products applied to same area

Missed dose

If a dose is missed, apply as soon as remembered unless it is nearly time for the next scheduled application. Do not double apply to compensate for missed dose. Resume regular dosing schedule. Extended treatment intervals beyond the recommended 4-day break should only be undertaken with medical supervision. Consistent application is crucial for optimal efficacy, but occasional missed doses are unlikely to significantly impact overall treatment outcome.

Overdose

Systemic toxicity may occur with excessive application, particularly over large areas or eroded skin. Symptoms include nausea, vomiting, diarrhea, CNS effects (confusion, dizziness), hematological abnormalities, and renal impairment. In case of suspected overdose, immediately remove medication by thorough washing with soap and water. Seek immediate medical attention. Supportive care should be provided; there is no specific antidote. Hemodialysis is not effective due to high protein binding.

Storage

Store at controlled room temperature (15–30°C). Keep container tightly closed and upright. Protect from light and moisture. Do not freeze. Keep out of reach of children and pets. Discard any unused product 3 months after first opening. Do not transfer to unlabeled containers. Do not use if solution discolors or precipitates form.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Podowart is a prescription medication requiring proper diagnosis and supervision by a qualified healthcare provider. Individual results may vary. Full prescribing information should be consulted before use. The manufacturer is not liable for incorrect application or adverse outcomes resulting from improper use.

Reviews

“After three cycles of Podowart, my patient’s recalcitrant plantar warts resolved completely without recurrence at 6-month follow-up. Superior to salicylic acid preparations.” – Dermatologist, UK

“Precise application is crucial. Patients who follow directions achieve excellent clearance rates with minimal side effects. A staple in my practice for appropriate candidates.” – Nurse Practitioner, US

“Effective but requires careful patient selection and education. Those who apply too generously experience significant local reactions. Good option when used correctly.” – General Practitioner, Australia